Captor Therapeutics (WAR:CTX) Total Liabilities: zł14.04 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CTX Captor Therapeutics SA WAR:CTX
38 GF Score
Price zł73.50
GF Value zł10.13
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Captor Therapeutics Total Liabilities?

Captor Therapeutics WAR:CTX -2.52% 38 Total Liabilities is zł14.04 Mil as of Mar. 2026. GuruFocus rates WAR:CTX with a GF Score™ of 38/100 and a GF Value™ of zł10.13 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Captor Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was zł14.04 Mil.

Captor Therapeutics's quarterly Total Liabilities increased from Sep. 2025 (zł11.27 Mil) to Dec. 2025 (zł16.54 Mil) but then declined from Dec. 2025 (zł16.54 Mil) to Mar. 2026 (zł14.04 Mil).

Captor Therapeutics's annual Total Liabilities declined from Dec. 2023 (zł28.07 Mil) to Dec. 2024 (zł23.02 Mil) and declined from Dec. 2024 (zł23.02 Mil) to Dec. 2025 (zł16.54 Mil).

Captor Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Captor Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Captor Therapeutics Total Liabilities Chart

Captor Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 19.34 16.68 28.07 23.02 16.54

Captor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.94 10.26 11.27 16.54 14.04
WAR:CTX
38GF Score
Captor Therapeutics SA WAR:CTX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Captor Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Captor Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.911+(1.515+8.7430063189231E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.115+0)
=16.54

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=40.022-23.481
=16.54

Captor Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.869+(1.059+-4.5796699765788E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.115+0)
=14.04

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=26.097-12.054
=14.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of zł14.04 Mil mean?
Captor Therapeutics (WAR:CTX) has a Total Liabilities of zł14.04 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Captor Therapeutics and its competitors.
Is Captor Therapeutics' Total Liabilities too high?
Captor Therapeutics' current Total Liabilities is zł14.04 Mil. Overall, Captor Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' Total Liabilities compare to VRTX and REGN?
Captor Therapeutics' Total Liabilities of zł14.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Captor Therapeutics and its competitors. Captor Therapeutics's current Total Liabilities is zł14.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.13, compared to a current price of zł73.50 — trading 625.6% above its estimated fair value. The current Total Liabilities is zł14.04 Mil. Captor Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current Total Liabilities is zł14.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued. The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13. GuruFocus considers Captor Therapeutics to be Significantly Overvalued.

Key valuation signals for WAR:CTX:

  • Total Liabilities: zł14.04 Mil
  • GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Captor Therapeutics Business Description

Address ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score

Get the complete analysis for WAR:CTX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł73.50
Price
zł10.13
GF Value